Olaparib (Lynparza®) in combination with bevacizumab (1L maintenance HRD positive ovarian cancer). HTA ID: 21011

Assessment Status NCPE Assessment Process Complete
HTA ID 21011
Drug Olaparib
Brand Lynparza®
Indication Olaparib in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.
Assessment Process
Rapid review commissioned 24/03/2021
Rapid review completed 28/04/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib in combination with bevacizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 31/05/2021
Pre-submission consultation with Applicant 04/10/2021
Full submission received from Applicant 07/02/2022
Preliminary review sent to Applicant 02/09/2022
NCPE assessment re-commenced 11/11/2022
Factual accuracy sent to Applicant 12/01/2023
NCPE assessment re-commenced 20/01/2023
NCPE assessment completed 27/01/2023
NCPE assessment outcome The NCPE recommends that olaparib in combination with bevacizumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations. September 2023